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Background: Exposure to particulate matter (PM) is a significant risk factor for increased cardiopulmonary morbidity
and mortality. The mechanism of PM-mediated pathophysiology remains unknown. However, PM is
proinflammatory to the endothelium and increases vascular permeability in vitro and in vivo via ROS generation.
Objectives: We explored the role of tight junction proteins as targets for PM-induced loss of lung endothelial cell
(EC) barrier integrity and enhanced cardiopulmonary dysfunction.
Methods: Changes in human lung EC monolayer permeability were assessed by Transendothelial Electrical
Resistance (TER) in response to PM challenge (collected from Ft. McHenry Tunnel, Baltimore, MD, particle size
>0.1 μm). Biochemical assessment of ROS generation and Ca2+ mobilization were also measured.
Results: PM exposure induced tight junction protein Zona occludens-1 (ZO-1) relocation from the cell periphery,
which was accompanied by significant reductions in ZO-1 protein levels but not in adherens junction proteins
(VE-cadherin and β-catenin). N-acetyl-cysteine (NAC, 5 mM) reduced PM-induced ROS generation in ECs, which
further prevented TER decreases and atteneuated ZO-1 degradation. PM also mediated intracellular calcium
mobilization via the transient receptor potential cation channel M2 (TRPM2), in a ROS-dependent manner with
subsequent activation of the Ca2+-dependent protease calpain. PM-activated calpain is responsible for ZO-1
degradation and EC barrier disruption. Overexpression of ZO-1 attenuated PM-induced endothelial barrier
disruption and vascular hyperpermeability in vivo and in vitro.
Conclusions: These results demonstrate that PM induces marked increases in vascular permeability via ROS-mediated
calcium leakage via activated TRPM2, and via ZO-1 degradation by activated calpain. These findings support a novel
mechanism for PM-induced lung damage and adverse cardiovascular outcomes.
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Ambient particulate matter (PM) poses a threat to na-
tional public health in urban environments and other
polluted areas throughout the US and around the world.
Epidemiological studies have shown associations of exposure
to low levels of urban particulate matter with increased* Correspondence: jggarcia@uic.edu
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reproduction in any medium, provided the orcardiopulmonary morbidity and mortality [1,2]. The assess-
ment of PM-induced health effects is challenging. Various
mechanisms have been proposed to explain the cardiopul-
monary health effects of PM including increased pulmonary
and systemic oxidative stress and inflammation, enhanced
coagulation, and altered cardiac autonomic function [3,4].
Airway epithelium represents a well-investigated target
for environmental pollutants such as PM. Exposure of
airway epithelium to airborne PM causes altered cyto-
kine/chemokine gene expression and increased produc-
tion of IL-1β, IL-6, IL-8 and TNF-α [5,6]. Now, the lungtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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get tissue. Exposure of the endothelium to PM or its ac-
tive components in the systemic circulation induces
significant systemic endothelial inflammation and dys-
function, even at low levels of exposure [7,8]. The water
soluble fraction of PM (up to 35-50%) can easily diffuse
through the epithelium/endothelial barrier to the sys-
temic circulation. Bioavailable transition metals present
in urban PM catalyze redox reactions in human lung
endothelium, which cause oxidative stress, increase the
production of inflammatory cytokines, and increase the
activation of NF-κB signaling pathways, all of which trig-
ger further endothelial damage [9]. Increased endothelial
monolayer permeability is also observed in inflammatory
pulmonary conditions such as acute lung injury (ALI),
acute respiratory distress syndrome (ARDS), and sepsis;
devastating lung disorders with mortality exceeding 30%,
as well as in more subacute and chronic inflammatory
disorders such as asthma [10,11].
We recently described a murine asthma model with
strong evidence for PM-mediated vascular barrier dys-
function with increased protein leakage into bronchoal-
veolar lavage (BAL), a marker of acute inflammatory lung
damage [12]. By assessment of direct effects on endothe-
lial barrier integrity in vitro, we further demonstrated that
the vascular hyperpermeability mediated by intratracheal
PM exposure is mainly dependent on acute endothelial
barrier disruption by PM [13]. Exposure of human lung
EC to PM resulted in significant ROS generation, which
mediates p38beta MAPK activation, leading to the phos-
phorylation of HSP27 [13]. Phosphorylated HSP27
facilitates the synthesis of stress fibers and formation
of paracellular gaps, which causes protein-containing
fluid to leak from the microvessel lumen to the lung
alveoli, leading to further pulmonary inflammation
[13]. However, these previous findings did not explain
the persistent character of PM-mediated endothelial
barrier disruption.
To fully examine PM-mediated vascular hyperperme-
ability, we explored effector targets such as tight junction
and adherens junction proteins, which are known to be
critical in EC barrier maintenance. We demonstrated that
PM exposure induced the relocation of tight junction pro-
tein Zona occludens-1 (ZO-1) from the cell periphery,
which was accompanied by a significant reduction in the
level of ZO-1 protein but not in the levels of adherens
junction proteins (VE-cadherin and β-catenin). PM also
mediated intracellular calcium mobilization via the transi-
ent receptor potential cation channel M2 (TRPM2), in a
ROS-dependent manner with subsequent activation of the
Ca2+-dependent protease calpain. PM-activated calpain is
responsible for ZO-1 degradation and EC barrier disrup-
tion. These observations not only provide new informa-
tion as to how PM disrupts endothelial tight junctions,but also represent the first evidence establishing the crit-
ical role of calpain signaling in modulating endothelial cell
barrier function under oxidative stress. These results in-
crease our understanding of PM-induced adverse cardio-
pulmonary outcomes. Moreover, as the newly
characterized signaling cascade of ROS/TRPM2/Calpain/
ZO-1 likely has fundamental roles in regulating the cyto-
skeleton under oxidative stress, these novel observations
may have broad applicability to vascular pathophysiology
in a variety of cell types.
Methods
Reagents and chemicals
Molecular mass standards, polyacrylamide gels, and pro-
tein assay reagents were purchased from Bio-Rad
(Hercules, CA). A number of antibodies were purchased
including ZO-1 (BD, Franklin Lakes, NJ), ZO-2, VE-
cadherin, β-catenin (Santa Cruz, Santa Cruz, CA), and
TRPM2 (Bethyl Labs, Montgomery, TX). Endotoxin
ELISA kit was purchased from Uscn Life Science (Wuhan,
China). TRPM2 siRNA was obtained from Dharmacon
(Lafayette, CO) and all other chemicals and reagents
were obtained from Sigma-Aldrich (St. Louis, MO)
unless stated otherwise.
PM
PM sample (0.1-0.3 μm of aerodynamic diameter) was
collected (April of 2005) from the Ft. McHenry Tunnel,
Baltimore, MD using a high-volume cyclone collector
[6,12-15]. The elemental composition (micrograms per
gram) of this PM sample representing the most abun-
dant constituents included: Fe 57 (132,545.9), Ca 43
(47,263.08), Al 27 (17,533.74), Cu 63 (8,777.886), Na 23
(8,068.263), Mg 25 (7,332.056), S 34 (6122.67), K 39
(5,102.741), Ti 47 (3,197.332), Mn 55 (2133.87), Zn 66
(645.60), Cr 52 (325.97), Pb 208 (122.07), Pb 204
(119.71), Sr 86 (111.01), Sr 88 (110.79), V 51 (76.30), Ni
60 (59.61), La 139 (21.27), Sn 118 (20.84), Sb 121
(15.76). No detectable endotoxin contamination was
found in the PM suspension (1 mg/ml) in water by LPS
ELISA kit (Uscn Life Science).
Human endothelial cell culture
Human lung microvascular ECs obtained from Lonza
(Basel, Switzerland) were cultured as previously described
[16] in EGMMV-2 complete medium (Lonza).
Transendothelial electrical resistance (TER)
Endothelial cells were grown to confluence in polycar-
bonate plates containing evaporated gold microelectrodes,
and TER measurements were continuously obtained using
an electrical cell-substrate impedance sensing system
(ECIS) (Applied Biophysics, Troy, NY) as previously
described in detail [17].
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Human microvascular lung ECs were transfected with
siRNA using siPORT Amine (Ambion, Austin, TX)
according to the manufacturer's protocol as we described
previously [13].
Measurement of intracellular Ca2+
ECs plated on glass cover slips were loaded with 5 μM
fura-2 AM (Invitrogen, Carlsbad, CA) in 1 ml of basal
medium as previously reported [18]. The cover slips with
ECs were inserted diagonally into 1 cm acrylic cuvettes
filled with 3 ml of basal medium at 37°C. Fura-2 fluores-
cence was measured with an Aminco-Bowman Series 2
luminescence spectrometer (SLM/Aminco, Urbana, IL)
at excitation wavelengths of 340 and 380 nm and emis-
sion wavelength of 510 nm. The cover slips with ECs
were then moved to 35 mm dishes, treated with PM sus-
pension, and incubated for 15 minutes at 37°C in 95% O2
and 5% CO2. After every 15-minute incubation, the cover-
slips were withdrawn from the dish and inserted back into
the acrylic cuvettes for Fura-2 fluorescence measurement,
then returned to the dish with the resuspended PM prep-
aration for another incubation period (15–60 min).
Animals
Male A/J mice (10–12 weeks of age; Jackson Laboratories,
Bar Harbor, ME) were housed in an environmentally con-
trolled animal facility at the University of Illinois at Chi-
cago (UIC) for the duration of the experiments. All animal
procedures follow the guideline of the UIC Animal Care
and Use Committee. PM (10 mg/kg, in 50 μl of saline)
was delivered via intratracheal aspiration 1 hr after NAC
or calpeptin treatment, as previously described [12,15].
Animals were sacrificed 24 hr after PM treatment, and
bronchoalveolar lavage (BAL) and lung tissue were col-
lected [12,19]. Total BAL cells were counted with a
hemocytometer. The BAL fluid was used for protein and
cytokine measurement (Bio-Rad, Hercules, CA) according
to the user’s manual.
Statistical analysis
Data are presented as group means ± SEM. We performed
statistical comparisons among treatment groups by
randomized-design two-way analysis of variance followed
by the Newman-Keuls post hoc test for more than two
groups, or by an unpaired Student’s t-test for two groups.
In all cases, we defined statistical significance as p < 0.05.
Results
PM induces endothelial barrier disruption and tight
junction protein degradation
We assessed human lung microvascular EC barrier
function as measured by transendothelial electrical re-
sistance (TER), a highly sensitive measurement ofpermeability. PM challenge (10–100 μg/ml) induced dose-
and time-dependent reduction in TER (Additional file 1:
Figure S1) or increases in FITC-dextran leakage through
EC monolayer (Additional file 1: Figure S2) [20], indicat-
ing a loss of EC barrier integrity. At the same time, PM
induced a time-dependent (1–6 hr) reduction of the levels
of tight junction proteins ZO-1 and ZO-2, but did not
affect levels of adhesion junction proteins VE-cadherin or
β-catenin (Figure 1A). No obvious cytotoxicity in the ECs
was found after PM challenge (100 μg/ml, 0–16 hr) with
MTT assay [13] or LDH release assay (Additional file 1:
Figure S3).
PM induces ROS-dependent EC barrier disruption and
ZO-1 degradation
PM (100 μg/ml) induced substantial time-dependent ROS
production in microvascular ECs as measured by DCFDA
oxidation, which peaked around 30–60 min (Additional
file 1: Figure S4). EC pretreatment with N-acetyl-cysteine
(NAC, 5 mM, 1 hr), an ROS scavenger, or PEG-catalase
(PEG-CAT, 250 U/ml, 1 hr), which degrades H2O2, pre-
vented PM-induced DCFDA oxidation by ROS (Add-
itional file 1: Figure S4). PM produced a sustained time-
dependent decrease in TER, with a maximal effect
observed at 100 μg/ml (80% decrease in TER), which is
similar to its effects on other endothelial cell types, as we
have reported previously [13]. NAC pretreatment (5 mM,
1 hr pretreatment) prevented PM-induced ZO-1 degrad-
ation (Figure 1B), while NAC (5 mM, 1–24 hr) does not
change ZO-1 protein levels by itself (Additional file 1:
Figure S5). After ECs were treated with PM (100 μg/ml,
6 hr), ZO-1 was relocated from the cell periphery and
degraded, which was followed by gap formation between
ECs. VE-cadherin, on the other hand, underwent no re-
location or degradation (Figure 1C). NAC pretreatment
(5 mM, 1 hr pretreatment) prevented PM-induced ZO-1
relocation and gap formation (Figure 1C). These data
strongly indicate that PM causes EC barrier disruption se-
lectively via oxidative tight junction protein degradation.
NAC (5 mM) or PEG-CAT (250 U/ml) pretreatment sig-
nificantly inhibited PM-induced EC barrier disruption as
measured by TER (Figure 1D). We also examined the
effects of another ROS scavenger EUK-134 on PM-
challenged ECs. As NAC, EUK (5 μM, 1 hr pretreatment)
attenuated PM-induced ZO-1 degradation and TER re-
duction (Additional file 1: Figure S6). These results further
confirmed that PM induces ROS-dependent EC barrier
disruption.
Activated calpain is required for PM-mediated ZO-1
degradation and EC barrier disruption
We previously demonstrated that high levels of ROS in
endothelial cells activate calpain, a calcium-dependent
protease [21]. We therefore investigated the role of calpain
Figure 1 PM induces ROS-dependent EC barrier disruption and ZO-1 degradation. (A) Human lung microvascular ECs grown on 6-well
plates were challenged with PM (100 μg/ml) for 0.5-6 hr. Cell lysates were analyzed by Western blotting with antibodies to ZO-1, ZO-2, VE-
cadherin, and β-catenin. (B) Human lung microvascular ECs grown on 6-well plates were challenged with PM (100 μg/ml) for 1 or 6 hr with or
without NAC (5 mM, 1 hr pretreatment). Cell lysates were analyzed by Western blotting. Changes in levels of ZO-1 are expressed as fold changes
and normalized to control. Shown are representative blots from three independent experiments. Relative levels of ZO-1 densitometry are shown
in bar graph under corresponding experimental conditions. N = 3. *p < 0.05 compared to control. **p < 0.05 compared to PM-6 hr group. (C)
Human lung microvascular ECs grown on glass chamber slides were challenged with PM (100 μg/ml) for 6 h with or without NAC (5 mM, 1 hr
pretreatment). VE-cadherin and ZO-1 localization was detected by immunofluorescence staining with antibodies to VE-cadherin and ZO-1. (D) ECs
grown on ECIS gold electrodes were pretreated with NAC (5 mM, 1 hr) or PEG-CAT (250 U/ml, 1 hr), then challenged with PM at 100 μg/ml.
Changes in TER were measured with the ECIS 6 hr post-PM treatment. *p < 0.05 compared to PM only group.
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induced a significant increase in calpain activity in ECs,
which was inhibited by selective calpain inhibitors ALLN
(30 μM, 1 hr pretreatment) and calpeptin (10 μM, 1 hr
pretreatment) (Figure 2A). PM-induced calpain activation
was also inhibited by BAPTA-AM (50 μM, 1 hr pretreat-
ment), a calcium chelator, and by NAC (5 mM, 1 hr pre-
treatment) (Figure 2A). We next determined the role of
calpain in PM-induced EC barrier disruption. PM-induced
reduction in TER was partially inhibited by calpeptin or
ALLN (Figure 2B). In parallel, ALLN and calpeptin also
significantly prevented PM-induced ZO-1 degradation, as
did chelation of intracellular calcium via BAPTA-AM
(Figure 2C).
PM induces calcium leakage via ROS-activated TRPM2
Addition of PM (100 μg/ml) to human lung microvascular
ECs produced slow time-dependent Ca2+ influx (Figure 3A;
Ca2+ influx is represented by an increase in the 340/380
ratio of Fura-2 AM.). Notably, this finding of increased
intracellular Ca2+ is in accordance with our previous find-
ing of increased activated calpain. Under oxidative stress, a
key member of the transient receptor potential (TRP) cat-
ion channel, member M2 (TRPM2), is activated and causesslow calcium influx [22]. We therefore examined the role of
activated TRPM2 in PM-stimulated calcium influx. Anti-
TRPM2 blocking antibody (5 μg/ml, 4 hr pretreatment) sig-
nificantly prevented the PM-induced Ca2+ transients com-
pared to ECs treated with control IgG (Figure 3B).
Reductions in TRPM2 protein expression (by siRNA) also
inhibited the PM-induced Ca2+ influx compared to ECs
treated with control siRNA (Figure 3C).
We next investigated whether TRPM2 activation was
ROS-dependent. Depletion of PM-induced ROS by NAC
(5 mM, 1 hr pretreatment) significantly prevented PM-
mediated calcium influx (Figure 3D). Under oxidative
stress, Poly ADP ribose polymerase (PARP) generates ADP-
ribose [23,24], which activates TRPM2 by binding to its
carboxyl terminus. The PARP inhibitor 3-aminobenzamide
(3-AB, 1 mmol/L, 1 hr pretreatment)significantly reduced
PM-induced Ca2+ influx (Figure 3E), which further con-
firmed that TRPM2 is activated by PM via ROS and PARP.
PM-activated TRPM2 promotes ZO-1 degradation by
calpain
We next investigated the role of TRPM2 activation in
EC barrier function and ZO-1 degradation. TRPM2 neu-
tralizing antibody (5 μg/ml, 4 hr pretreatment)
Figure 2 Activated calpain is required for PM-mediated ZO-1 degradation and EC barrier disruption. (A) Human lung microvascular ECs
grown in 60-mm dishes to approximately 95% confluence were treated with ALLN (30 μM), calpeptin (CALP, 10 μM), NAC (5 mM), or BAPTA-AM
(50 μM) for 1 hr, and then challenged with PM (100 μg/ml) for 1 hr. Cell lysates were subjected to calpain activity assay by using the calpain
activity kit (Calbiochem). Calpain activity was normalized to protein concentration and expressed as fold changed compared to control. *p < 0.05
compared to control. **p < 0.05 compared to PM only group. (B) ECs grown on ECIS gold electrodes were treated with ALLN (30 μM), calpeptin
(CALP, 10 μM) for 1 hr, and then challenged with PM (100 μg/ml). Changes in TER were measured with ECIS. *p < 0.05 compared to PM only
group. (C) ECs grown on 6-well plates were treated with ALLN (30 μM), calpeptin (CALP, 10 μM), or BAPTA-AM (50 μM) for 1 hr, and challenged
with PM (100 μg/ml) for 1–6 hr. Cell lysates were analyzed by Western blotting with antibody to ZO-1. Changes in levels of ZO-1 are expressed as
fold changes and normalized to β-actin. Shown are representative blots from three independent experiments. *p < 0.05 compared to PM-1 hr
group. **p < 0.05 compared to PM-6 hr group.
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(Figure 4A). TRPM2 siRNA (100 ng/ml), which downre-
gulated TRPM2 protein level (Figure 4B), also inhibited
PM-induced ZO-1 degradation (Figure 4C). In parallel,
antagonizing TRPM2 by either TRPM2 antibody (5 μg/ml,
4 hr pretreatment) or TRPM2 siRNA (100 ng/ml) signifi-
cantly prevented PM-induced EC barrier disruption
(Figure 4D-E), as indicated by TER measurements.
ROS scavenging or calpain inhibition prevents PM-
induced pulmonary inflammation and ZO-1 loss
A PM-mediated murine model of pulmonary inflamma-
tion has been well established [12]. We investigated the
role of ROS and calpain in PM-induced pulmonary in-
flammation by examining protein leakage, white blood cellinfiltration (inflammatory leukocytes), and the release of
proinflammatory cytokines into BAL fluids (Figure 5).
Pre-administration of NAC (150 mg/kg) or calpeptin
(1 mg/kg) 1 hr before PM challenge (10 mg/kg, 24 hr) sig-
nificantly attenuated PM-induced protein leakage into
BAL fluids (~ 50% reduction, Figure 5A). PM challenge
(10 mg/kg, 24 hr) resulted in an increase in inflammatory
leukocytes, e.g. neutrophils and eosinophils [12,15], in
BAL fluids (Figure 5B). Pre-administration of NAC
(150 mg/kg) or calpeptin (1 mg/kg) attenuated PM-
induced inflammatory leukocyte infiltration. Furthermore,
NAC (150 mg/kg) or calpeptin (1 mg/kg) attenuated the
release of PM-induced proinflammatory cytokines IL-6
and THF-α into BAL (~50% inhibition, Figure 5C-D).
These results suggest that ROS scavenging by NAC or
Figure 3 PM induces calcium leakage via ROS-activated TRPM2. (A) Human lung microvascular ECs were plated on glass cover slips and
loaded with 5 μM Fura-2 AM in 1 ml of basic medium. ECs were rinsed twice and treated with PM (100 μg/ml). Fura-2 fluorescence was
measured at excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm (0–60 min). Fura-2 has excitation wavelengths of
380 nm in its free form and 340 nm when it is bound to calcium; therefore, relative calcium concentrations are represented by the ratio of 340/
380. (B) ECs plated on glass cover slips were treated with TRPM2 antibody or control IgG (5 μg/ml, 4 hr pretreatment). ECs were then rinsed
twice and subjected to the same calcium measurement procedures with PM treatment (100 μg/ml, 0–60 min). *p < 0.05 compared to control IgG
group at the same time point. (C) ECs were transfected with TRPM2 siRNA or control siRNA for 48 hrs. ECs were then rinsed twice and subjected
to the same calcium measurement procedures with PM treatment (100 μg/ml, 0–60 min). EC cell lysates were analyzed by Western blot with
antibodies to TRPM2 and β-actin to confirm silencing. *p < 0.05 compared to control siRNA group at the same time point. (D-E) ECs plated on
glass cover slips (95% confluent) were treated with NAC (5 mM, 1 hr pretreatment) or 3-AB (1 mM, 1 hr pretreatment). ECs were then rinsed twice
and subjected to the same calcium measurement procedures with PM treatment (100 μg/ml, 0–60 min). *p < 0.05 compared to PM-only group at
the same time point.
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protective effects including enhancement of lung endothe-
lial barrier function, reduction of inflammatory cell infil-
tration, and prevention of proinflammatory cytokine
release in the lungs of PM-challenged mice. We next
examined tight junction ZO-1 levels in the PM-exposed
lung. PM challenge (10 mg/kg, 24 hr) induced a significant
reduction of ZO-1 protein levels in the murine lung,
while pre-administration of NAC (150 mg/kg) or calpeptin
(1 mg/kg) 1 hr before PM challenge attenuated PM-
induced ZO-1 loss from lung tissues. Taken together,
these data suggest a crucial role for the ROS-calpain-ZO-
1 signaling pathway in the regulation of EC barrier disre-
gulation in PM-mediated pulmonary inflammation.Over-expression of endothelial ZO-1 attenuates PM
mediated endothelial barrier disruption in vitro and
pulmonary inflammation in vivo
To further confirm the critical role of ZO-1 degradation
in EC barrier disruption in vitro and pulmonary inflam-
mation in vivo, we next examined the beneficial effects of
over-expressing ZO-1 protein in endothelial cells in vitro
and in vivo. ZO-1 over-expression (Figure 6A) signifi-
cantly (but not completely) attenuated PM-induced EC
barrier disruption (Figure 6B). These facts demonstrate
that endothelial ZO-1 loss contributes to PM-mediated
EC barrier disruption. We next over-expressed ZO-1
in vivo by a liposome delivery system labeled with ACE
antibody, which successfully over-expressed ZO-1 in
Figure 4 PM-activated TRPM2 promotes ZO-1 degradation by calpain. (A) Human lung microvascular ECs grown in 6-well dishes to
approximately 95% confluence were treated with TRPM2 antibody or control IgG (5 μg/ml) for 4 hr, and then challenged with PM (100 μg/ml) for
6 hr. Cell lysates were analyzed by Western blotting with ZO-1 antibody. Changes in levels of ZO-1 are expressed as fold changes and normalized
to β-actin. Shown are representative blots from three independent experiments. *p < 0.05 compared to control. **p < 0.05 compared to PM
challenge. (B) ECs grown in 6-well dishes to approximately 80% confluence were treated with TRPM2 siRNA or control siRNA (100 ng/ml) for
48 hr, and cell lysates were analyzed by Western blotting with ZO-1 antibody. (C) ECs grown in 6-well dishes to approximately 95% confluence
were treated with TRPM2 siRNA or control siRNA (100 ng/ml) for 48 hr, and then challenged with PM (100 μg/ml) for 6 hr. Cell lysates were
analyzed by Western blotting with ZO-1 antibody. Changes in levels of ZO-1 are expressed as fold changes and normalized to β-actin. Shown are
representative blots from three independent experiments. *p < 0.05 compared to control. **p < 0.05 compared to PM challenge. (D) ECs grown
on ECIS gold electrodes were treated with TRPM2 antibody or control IgG (5 μg/ml) for 4 hr, and then challenged with PM (100 μg/ml). Changes
in TER were measured with ECIS. *p < 0.05 compared to PM-challenged group. (E) ECs grown on 100 mm dishes were treated with TRPM2 siRNA
or control siRNA (100 ng/ml) for 48 hr, and then plated onto gold electrodes for ECIS measurement. 24 hours after replating, the ECs were
challenged with PM (100 μg/ml) and changes in TER were measured with ECIS. *p < 0.05 compared to PM-challenged group.
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significantly attenuated BAL protein leakage (Figure 6D),
BAL white blood cell infiltration (Figure 6E), and the re-
lease of proinflammatory cytokine IL-6 into BAL
(Figure 6F), indicating the crucial role of ZO-1 loss in me-
diating PM-induced pulmonary inflammation and lung
vascular hyperpermeability.
Discussion
The most significant finding of the present study is the
novel characterization of a ROS-dependent pathway thatcauses calpain-dependent endothelial ZO-1 degradation in
response to PM. These data represent the first evidence
that calpain signaling, via calcium leakage from activated
TRPM2 by ROS, plays a critical role in modulating endo-
thelial cell barrier function, resulting in tight junction pro-
tein ZO-1 degradation (Additional file 1 Figure S7). The
consequence of ZO-1 degradation is sustained endothelial
hyperpermeability and persistent lung inflammation, both
of which contribute to variety of acute or chronic cardio-
vascular disorders [25,26]. These effects were also
observed with other types of PM samples (1648a from
Figure 5 NAC and calpeptin pretreatment reduces PM-induced pulmonary inflammation and ZO-1 loss in murine lung. AJ mice (n = 4)
were treated NAC (150 mg/kg, intraperitoneal injection) or calpeptin (CALP, 1 mg/kg, intraperitoneal injection) 1 hr before PM challenge (10 mg/
kg, intratracheal aspiration). After 24 hr, (A) protein concentration of BAL fluids was measured, (B) total white blood cell (WBC) in BAL were
counted, and (C-D) IL-6 and TNF-α levels in BAL were measured. (E) Protein was extracted from the mouse lungs and analyzed by Western
blotting using ZO-1 and β-actin antibodies. Changes in levels of ZO-1 are expressed as fold changes and normalized to β-actin. *p < 0.05
compared to control. **p < 0.05 compared to PM-challenge. (F) BAL cellularity were examined by cytospin slides, and lung tissues were examined
by hematoxylin and eosin (H&E) staining.
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collected from New York city or Baltimore, data not
shown), indicating a selective pathogenesis pathway by
PM pollution.
Previous studies report that PM triggers the generation
of reactive oxygen species or ROS mainly from dysfunc-
tional mitochondria [27,28], and we also noticed the
massive generation of ROS by this PM sample is also
mainly from mitochondria (unpublished observation). The
high iron level of this particular PM might also contribute
to the ROS generated via Fenton reactions. ROS released
endogenously, have been implicated in the pathophysi-
ology of several lung diseases, including asthma and
COPD, as the biochemical mechanisms underlying the
urban PM-induced airway inflammation and toxicity [29].
ROS are highly reactive and cause deleterious gene, pro-
tein, and tissue effects. ROS are increased in BAL or
exhaled breath condensate from patients with inflamma-
tory lung injuries and from people with cardiopulmonarydisease who have been exposed to PM [30,31]. This
response may reflect the high oxidative potential of fine
and ultrafine particulates. Residual oil fly ash (ROFA) and
PM1.7-3.5 cause pulmonary inflammation mediated by
oxidative stress [32,33]. In vivo, exposing rats to PM leads
to the formation of free radicals in the lung [34]. Since
cardiovascular disease is considered a risk factor of PM-
related mortality and morbidity, it is interesting to note
that spontaneously hypertensive rats, when exposed to
PM, were more susceptible to pulmonary (inflammatory
injury) and cardiovascular complications (acute depression
of ECG activity) in an oxidant-dependent manner [35].
Besides ROS, PM might trigger adverse outcomes via
other potential mechanisms including nonselective phos-
phatase inhibition (by vanadium) or competitive ion chan-
nel inhibition (by nickel) due to the complex and variable
chemical components.
In this study, we first define a novel pathway that med-
iates ROS-dependent tight junction disruption upon
Figure 6 Over-expression of endothelial ZO-1 attenuates PM-induced EC barrier disruption in vitro and pulmonary inflammation
in vivo. (A) Human lung microvascular EC were grown to 60% confluence and treated with ZO-1 expression plasmid with X-fect reagent for
48 hr, and over-expression of ZO-1 protein was confirmed by Western blot. (B) The ECs were then challenged with PM (100 μg/ml), and changes
in TER after 6 hr were measured with ECIS. *p < 0.05 compared to PM-challenged group. AJ mice were treated with ZO-1 expression plasmid with
an ACE antibody-conjugated liposome delivery system (5 mg/kg) for 3 days, then challenged with PM (10 mg/kg). After 24 hr of PM exposure, (C)
lung ZO-1 levels were analyzed with Western blot. Shown is one of the three repeated blots. BAL was collected and (D) protein content, (E) total
white blood cell, and (F) IL-6 levels were measured. N = 4. *p < 0.05 compared to PM-challenged group. **p < 0.05 compared to control.
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occludens, are the most apical component of the intercel-
lular junctional complex, which also includes adherens
junctions, desmosomes, and gap junctions [36]. ZO-1 was
the first tight junction protein to be identified, and ZO-2
and ZO-3 were later isolated as proteins that co-
immunoprecipitated with ZO-1 [37,38]. ZO-1 is a periph-
eral membrane-associated component of the cytoplasmic
plaque of tight junctions and is found ubiquitously within
tight junctions of epithelial and endothelial cells [39]. ZO-
1 interacts with many cellular proteins via its multiple
protein-binding domains. ZO-1 has been reported to
interact with other ZO family members or claudins via the
PDZ domains [40,41]. ZO-1 interacts with the C-terminus
of occludin with its GuK domain and the acidic domain
[42]. The proline-rich C-terminus of ZO-1 mediates its
binding to F-actin in vitro, and thus links it to the cyto-
skeleton [43]. Clearly, ZO-1 interacts with a wide variety
of cell skeleton components and plays a central role in or-
chestrating tight junction complexes. Any dysregulation of
ZO-1 in endothelial cells by extracellular stimuli, such as
virus shell proteins or alcohol, leads to persistent tight
junction disruption and vascular hyperpermeability.Calpain is a regulator of endothelial integrity which
helps control fundamental cellular processes including
cytoskeletal remodeling, membrane fusion, cell prolifera-
tion and differentiation, and activation of proteolytical
cascades leading to apoptosis [44,45]. Under oxidative
stress, activated calpain cleaves eNOS and cytoskeletal
proteins and induces apoptosis [21,46-48]. Particulate
matter induces endothelial cell intracellular oxidative
stress, which leads to the activation of calpain, one of the
major cytoskeletal regulators. Here we describe the cleav-
age of tight junction protein ZO-1 by activated calpain
both in vitro and in vivo, indicating that calpain plays a
central role in PM-induced endothelial barrier disruption
and vascular hyperpermeability. In addition, as activated
calpain cleaves other critical cytoskeletal proteins includ-
ing ezrin and MARCKS protein, the contribution of the
other cytoskeletal proteins to the EC hyperpermeability
induced by PM needs to be further investigated.
Oxidative calcium influx is mediated by plasma mem-
brane cation-permeable ion channels. The transient recep-
tor potential protein (TRP) and its homologs are cation
channels with a tetramer secondary structure which senses
diverse stimuli from the extracellular and intracellular
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subfamilies. TRPM2, a member of the TRP channel M2
subtype, is a calcium-permeable channel activated by intra-
cellular messengers such as ADP-ribose [50]. Massive ROS
burden induced by PM contributes to DNA oxidation and
damage, which activates poly-ADP ribose polymerase
(PARP) to initiate DNA repair mechanisms. PARP binds to
single-stranded and double-stranded DNA breaks and cat-
alyses the breakdown of NAD into nicotinamide and ADP-
ribose, the intracellular agonist of TRPM2 [22,51,52]. Oxi-
dative stress-mediated activation of the PARP pathway
serves as the major source of free ADP-ribose production
in endothelial cells [53]. Intracellular ADP-ribose activates
TRPM2, allowing calcium ions to enter the cell, which in
turn trigger numerous physiological and pathological
processes.
An important limitation of our study is the high dose
of PM that we employed. With 10–30 μg/m3 ambient
PM level in the US or Europe, it is hardly to achieve a
high level of acute PM exposure. While 100 μg/ml
(in vitro) or 10 mg/kg (in vivo) are typical doses used in
particulate matter toxicology studies [12,13,27,54-56].
With an assumed ambient PM level of 20 μg/m3, one
man with 70 kg body weight and 8 m3/minute respir-
ation rate would receive a dose of 10 mg/kg correspond-
ing to about 16 years of exposure with 50% deposition
rate. As noted, a lot of cities in the developing countries
still have high levels of ambient PM. A report by world
bank [57] stated that in the year of 2006, extremely high
PM10 levels still existed in a lot of cities (μg/m3): Nyala
in Sudan (359), Kano in Nigeria (283), Hyderabad in
Pakistan (239), Maroua in Cameroon (228), Muzaffarpur
in India (218), N'DJAMENA in Chad (204), Segou in
Mali (200), Erbil in Iraq (195), Shubra-El-Khema in
Egypt (186), DHAKA in Bangladesh (174). Over 13 mil-
lion people live with more than 200 μg/m3 ambient PM
in Pakistan, which results over 20 mg inhaled per week,
or 16 mg/kg per year.
Extensive epidemiologic and experimental evidence has
demonstrated that particulate air pollution directly causes
cardiopulmonary damage. Our observations demonstrate a
novel mechanism of PM-mediated disruption of endothelial
barrier function which is attributable to ZO-1 degradation
by calpain, which is activated by extracellular calcium leak-
age through oxidant-sensitive TRPM2 channels. Therefore,
inhibition of ROS/TRPM2/calpain/ZO-1 degradation may
provide useful therapeutic strategies for the treatment of
endothelial barrier dysfunction and lung inflammation.
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Additional file 1: Figure S1. (A-B) PM induces dose-dependent
reduction in transendothelial resistance (TER). (C) PM induces dose-
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(5 mM, 1-24 hr) does not change ZO-1 protein levels in human ECs.
Figure S6. EUK-134 (5 μM, 1 hr pre-treatment) attenuates PM (100 μg/ml,
6 hr)-induced ZO-1 degradation and TER reduction. Figure S7. We
hypothesize that PM induces EC barrier disruption in delayed phase (via
ZO-1 degradation) and acute phase (via stress fiber formation).
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